M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano 9 - 10 aprile 2010.

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. A Validated Risk Score for In-hospital Mortality in Patients with Heart Failure from the American.
Advertisements

Associations Between Outpatient Heart Failure Process of Care Measures and Mortality Gregg C. Fonarow, Nancy M. Albert, Anne B. Curtis, Mihai Gheorghiade,
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Strategie terapeutiche Strategies of Medical Therapy Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
Evolving Patterns Of Use Of Aldosterone Inhibition In Chronic Heart Failure; A Report From Get With The Guidelines HF Nancy M. Albert, Clyde W. Yancy,
Heart Failure with Normal Systolic Function: Better or Worse Prognosis? Maria Rosa Costanzo, M.D., F.A.C.C, F.A.H.A. Medical Director, Midwest Heart Specialists.
חזק בהגנה לבבית Valsartan in Heart Failure
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
“ Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients with Ischemic Stroke ” Gregg C. Fonarow,
Overview of Adult Cardiovascular Disease Social Security Administration Compassionate Allowances Outreach Hearing on Cardiovascular Disease and Multiple.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
analysis from the SHIFT study
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Fonarow GC, et al. J Am Coll Cardiol. 2007;50:768  777. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized.
Role of Rosuvastatin in the Treatment of Dyslipidemia
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Clinical Impact of Adherence to Pharmacotherapeutic Guidelines on the Outcome in Patients with Chronic Heart Failure Suntheep Batra, M.Pharm Department.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
Incidence of and Risk Factors for Sudden Cardiac Death in Children with Dilated Cardiomyopathy: A Report from the Pediatric Cardiomyopathy Registry Elfriede.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
Get With The Guidelines-Heart Failure Gregg C. Fonarow, MD Eliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology Director, Ahmanson-UCLA.
אי ספיקת לב ופרפור פרוזדורים - מגדר ד"ר א. שוטן מכון הלב הילל יפה, חדרה.
Influence of Age on the Management of Heart Failure: Findings from Get With the Guidelines-HF DE Forman, CP Cannon, AF Hernandez, L Liang, CW Yancy, GC.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Heart failure and comorbidities
Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2007 Hypertension as a Public Health Risk January, 2007.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
NTproBNP for the Exclusion of Heart Failure Richard Blakey.
Regional Differences in Heart Failure Medication Changes During Acute Heart Failure Hospitalization: Findings From the PROTECT Trial Robert J. Mentz, Gad.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.
CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.
Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Revascularization in Patients With Left Ventricular Dysfunction:
Recently Diagnosed vs Chronic HF Associated with Better Outcomes
Cardiovacular Research Technologies
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Equipoise ”Balance of forces or interests”
The percentage of subjects with de novo development of renal function impairment (GFR
Creatinine clearance (mL/min) n All-cause mortality (%)
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
Prevalence of statin and beta-blocker use by clinical presentation
Nazem Akoum, MD, MS, FACC, FHRS Associate Professor of Medicine
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Presentation transcript:

M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010

Genders and Heart Failure: Difference and Analogies Prognostication Assessment in Heart Failure Women: Do we have enough skill? Mariell Jessup MD, FAHA, FACC Professor of Medicine University of Pennsylvania

Women in low LVEF heart failure trials.

1063 persons 45% survival at 5 years Circ Heart Failure 2008; 1:91-97

“Long-term coffee consumption was not associated with an increased risk of stroke in women. In contrast, our data suggest that coffee consumption may modestly reduce risk of stroke. Nurses Health Study

Clinical –Age –Gender –Etiology –HR/BP –BMI –Respiratory Rate –HF Signs/Symptoms –Recent Hospitalization –LVEF –Atrial Fibrillation –VT/VF Comorbidities –Cancer/PVD/CVA –Diabetes Mellitus –Smoking/COPD/Sleep Apnea –Alcohol –Liver Disease –Depression –Dialysis Functional –NYHA Class Prior to Admit and 30 day Laboratory - Admit and D/C –Sodium –BUN/Cr –Total Bilirubin –AST/ALT/Albumin –Hgb/WBC/RDW/%Lymphs –Uric acid –Cholesterol –BNP –Troponin Medications/Device - Admit and D/C –Diuretics - Type and Daily Dose –ACEI –ARB –CCB –B blocker –Aldosterone Blockers –Hydralazine/Nitrate –Statin –ASA/NSAID/Clopidogrel –Digoxin –BiV ± ICDs –Inotrope Use Prognostic Predictors in HF

Goldberg, Jessup Circulation 2007; 116:360

ADHERE ® CART: Predictors of Mortality SYS BP 115 n=24,933 n=7, %n=5, %N=2, %n= %n=1, %n=4, %n=20,834 BUN 43 N=33,324 Greater thanLess than 2.68%n=25, %n=7,202 Cr ,045 Highest to Lowest Risk Cohort OR 12.9 (95% CI ) Fonarow GC, et al. Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology. JAMA. 2005;293: ,324 patients!

JACC 2010; 55: 872

JACC 2008; 52: , 612 patients

The Prognostic Value of Maximal Oxygen Consumption VO 2 > 14 ml/Kg/min VO 2 ≤ 14 ml/Kg/min (listed)* VO 2 ≤ 14 ml/Kg/min (not listed)* Circulation 1991;83: * p 14

O’Neill et al. Circulation 2005; 111:2313

2331 patients 28% women NYHA II-IV Low LVEF

BNP Concentration for the Prediction of Clinical Events Harrison A. Ann of Emerg Med 2002; 39: ) % 5% 10% 15% 20% 25% 30% 35% 40% 45% BNP < 230 pg/ml BNP pg/ml BNP > 480 pg/ml Death or Heart Failure Hospitalization Days N = 325

JACC 2008; 52: NT-proBNP: 1078 pg/ml

In this population of women, higher baseline blood levels of NT-proBNP were associated with the future development of SCD, and this relationship was independent of established risk factors for CHD and/or SCD.

Stempfle et al. J Heart Lung Transplant 2008;27:222

Mullens et al. Am J Cardiol 2008; 101:1297

Risk Stratification for Mortality with HF Seattle Heart Failure Score 1 Year ROC

Circ Heart Failure 2008; 1: Health Aging and Body Composition

Aaronson et al. Circulation 1997;95: Heart Failure Survival Score

Risk Stratification I would counsel my heart failure patients to consider advanced therapies (such as VAD or transplant) or discuss end-of-life issues if the predicted annualized mortality rate was: % % % % 5. > 50% 6. I would not counsel the patients for either approach